Global Celecoxib Market Strategic Research Report

Scope of the Report

The global Celecoxib market size is predicted to grow from US$ 1,651 million in 2025 to US$ 2,850 million in 2032; it is expected to grow at a CAGR of 8.2% from 2026 to 2032.

Celecoxib capsules (patent brand name: CELEBREX), is a new generation of non-steroidal anti-inflammatory and analgesic drugs, mainly through the selective inhibition of coX-2 (COX-2) to inhibit the production of prostaglandins, achieve anti-inflammatory and analgesic effects.

The drug is used to relieve symptoms and signs of osteoarthritis and rheumatoid arthritis in adults and has fewer gastrointestinal side effects than traditional non-steroidal anti-inflammatory drugs.

Data show that more than 400 million people worldwide are currently affected by joint diseases.

The prevalence of osteoarthritis is 17 percent among people aged 40, 62 percent among people over 60 and 80 percent among people over 75.

The number of patients with arthritis in mainland China is more than 10% of the total population, well over 100 million, and the incidence of arthritis increases with age, and the number of patients is still increasing.

At present, the burden of chronic diseases will increase by 40% due to the aging of the population.

As the population ages, anti-inflammatory and anti-rheumatic drugs will enter a phase of rapid growth.

Globally, whether prescription drugs or non-prescription drugs, Xibu is widely used in clinical practice.

At present, the best seller in the international market is Celixib. Celixib market will continue to grow steadily in the next few years.

At present, the global Celecoxib market is basically occupied by Pfizer, which has formed an oligopoly.

It accounted for 63.39% of the global market in 2019.

As of 2019, China relies entirely on Pfizer for celecoxib imports.

Since 2020, some domestic drug companies have been gradually approved by FDA and CFDA. The introduction of celecoxib generic drugs by local companies will break the monopoly of import.

This report presents a comprehensive overview of the global Celecoxib market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 50mg
• 100mg
• 200mg
• 400mg

Segment by Application

• Rheumatoid arthritis
• osteoarthritis
• Acute pain
• Musculoskeletal pain
• Other diseases

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Celecoxib market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Rheumatoid arthritis, osteoarthritis, Acute pain evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact